Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Scancell Hldgs Plc (SCLP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.65 -0.20    -2.03%
16:35:59 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 720,027
  • Bid/Ask: 9.50 / 11.00
  • Day's Range: 9.50 - 9.88
Type:  Equity
Market:  United Kingdom
ISIN:  GB00B63D3314 
SEDOL:  B63D331
Scancell 9.65 -0.20 -2.03%

Scancell Company Profile

 
Read the Scancell company profile to learn more about the business and the management team. View Scancell Hldgs Plc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

40

Equity Type

ORD

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Contact Information

Address Bellhouse Building Unit 202
Sanders Road Oxford Science Park Oxford, OX4 4GD
United Kingdom
Phone 44 18 6558 2066
Fax -

Top Executives

Name Age Since Title
Lindy Gillian Durrant - 2008 Founder, CEO, Chief Scientific Officer & Director
Susan Elizabeth Clement-Davies 59 2020 Independent Non-Executive Deputy Chair
Jean-Michel Yves Sylvain Cossery 63 2023 Non-Executive Chairman
Martin H. Diggle 62 2019 Non-Executive Director
Ursula M. Ney 72 2019 Independent Non-Executive Director
Sathijeevan Nirmalananthan 38 2023 CFO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SCLP Price Commentary

Write your thoughts about Scancell Hldgs Plc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
A L Pear
A L Pear Sep 27, 2023 10:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Amazing results from last trial. Exciting to see what the next set brings. Check out the posters from the Milan conference.
Pro Fessor
Pro Fessor Feb 20, 2021 17:40
Saved. See Saved Items.
This comment has already been saved in your Saved Items
how long till SCLP vaccine is on market ?one more year?
Eurig Davies
Eurig Davies Dec 21, 2020 10:23
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Market starting to realise that different types of vaccines have value. This company has developed a vaccine that should be a longer term answer...
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email